{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:45:49Z","timestamp":1792053949578,"version":"4.4.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":262,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82575012"],"award-info":[{"award-number":["82575012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science & Technology Program of Jiangsu Commission of Health","award":["MQ2024039"],"award-info":[{"award-number":["MQ2024039"]}]},{"name":"Developing Program for High-level Academic Talent in Jiangsu Hospital of Chinese Medicine","award":["y2026rc55"],"award-info":[{"award-number":["y2026rc55"]}]},{"name":"Developing Program for High-level Academic Talent in Jiangsu Hospital of Chinese Medicine","award":["y2026rc01"],"award-info":[{"award-number":["y2026rc01"]}]},{"name":"Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology","award":["BE2016809"],"award-info":[{"award-number":["BE2016809"]}]},{"name":"Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology","award":["BE2017639"],"award-info":[{"award-number":["BE2017639"]}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["035062002003c"],"award-info":[{"award-number":["035062002003c"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nanjing Science and Technology Development Program","award":["201503011"],"award-info":[{"award-number":["201503011"]}]},{"name":"Foundation of Jiangsu Hospital of Chinese Medicine","award":["Y19030"],"award-info":[{"award-number":["Y19030"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytokine release syndrome (CRS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Macrophages\/monocytes are mediators of CRS. Tripterygium glycosides is an immunomodulator, which could inhibit macrophages\/monocytes in animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two patients with relapsed and refractory hematological malignancies developed CRS after receiving CAR-T therapy. They received short-term Tripterygium glycosides orally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both patients showed rapid mitigation of fever with evidently decrease in elevated inflammatory cytokines within 72\u2005hours. The patients\u2019 monocytes diminished remarkably, while CAR-T cells were negligibly affected. Treatment of 30\u2005ng\/ml triptolide in ex vivo cultured patients\u2019 blood for 24\u2005hours selectively deplete over half of monocytes. Single-cell RNA sequencing suggested selective depletion of CD14 + CD16+ monocytes with decreased pro-inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The low-cost and orally available Tripterygium glycosides could be a promising alternative for CAR-T induced CRS, as well as other diseases complicated with CRS, e.g. coronavirus disease 2019.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/immadv\/ltag021","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:28:04Z","timestamp":1789756084000},"source":"Crossref","is-referenced-by-count":0,"title":["CAR-T cell-induced cytokine release syndrome is rapidly alleviated by Tripterygium glycosides: a case series and laboratory examination study"],"prefix":"10.1093","volume":"6","author":[{"given":"Zuqiong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tian","sequence":"additional","affiliation":[{"name":"Central Laboratory\/Research Center of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1443-1023","authenticated-orcid":false,"given":"Biqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Central Laboratory\/Research Center of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtu","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbin","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, the Affiliated Hospital of Xuzhou Medical University , Xuzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital of Chinese Medicine\/the Affiliated Hospital of Nanjing University of Chinese Medicine , Nanjing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026101504073646700_ltag021-B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2026101504073646700_ltag021-B2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026101504073646700_ltag021-B3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3389\/fphar.2019.01469","article-title":"Application and mechanisms of triptolide in the treatment of inflammatory diseases-a review","volume":"10","author":"Yuan","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026101504073646700_ltag021-B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.chembiol.2013.12.009","article-title":"TAB1: a target of triptolide in macrophages","volume":"21","author":"Lu","year":"2014","journal-title":"Chem Biol"},{"key":"2026101504073646700_ltag021-B5","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"2026101504073646700_ltag021-B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101504073646700_ltag021-B7","doi-asserted-by":"publisher","first-page":"e14604","DOI":"10.1097\/MD.0000000000014604","article-title":"Clinical efficacy and safety of Tripterygium wilfordii Hook in the treatment of diabetic kidney disease stage IV: a meta-analysis of randomized controlled trials","volume":"98","author":"Ren","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026101504073646700_ltag021-B8","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026101504073646700_ltag021-B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jep.2014.06.006","article-title":"Triptolide: progress on research in pharmacodynamics and toxicology","volume":"155","author":"Li","year":"2014","journal-title":"J Ethnopharmacol"},{"key":"2026101504073646700_ltag021-B10","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101504073646700_ltag021-B11","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.71110","article-title":"Tripterygium glycosides alleviates hemophagocytic lymphohistiocytosis accompanied with aggressive NK cell leukemia and Epstein-Barr virus infection","volume":"98","author":"Chen","year":"2026","journal-title":"J Med Virol"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltag021\/71235590\/ltag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag021\/71235590\/ltag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag021\/71235590\/ltag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:07:46Z","timestamp":1792051666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltag021\/8818115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltag021","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,31]]},"article-number":"ltag021"}}